Skip to main content
. 2012 Sep-Oct;5(6):347–358.

Table 3.

Physician-Reported Prescribing Patterns, by LID Severity

Disease severity Physicians, N (N = 7) Drugs, doses, and frequency
Mild LIDs, 32% (278 patients)
Monotherapy (includes fixed-dose combination medications) 4 Dopamine agonists:

  • Pramipexole (Mirapex)a 3 times daily (n = 2)

  • Ropinirole (Requip)a 4 times daily (n = 2)
Combination therapy 1

  • Ropinirole 3 mg + carbidopa/levodopa/entacapone (Stalevo 100) 3 times daily
No medication 1 Stated did not understand the question
No answer 1 NA
Moderate LIDs, 37% (316 patients)
Monotherapy (includes fixed-dose combination medications) 2 Dopamine agonists:

  • Pramipexole (Mirapex)a 3 times daily (n = 2)
Combination therapy 4 Cited medicationsb:

  • Amantadine (Symmetrel)

  • Generic amantadine

  • Carbidopa/levodopa/entacapone

  • (Stalevo 100)

  • Entacapone (Comtan)

  • Pramipexole (Mirapex)

  • Rasagiline mesylate (Azilect)

  • Ropinirole (Requip)
No medication 1 Stated did not understand the question
Severe LIDs, 31% (262 patients)
Monotherapy (includes fixed-dose combination medications) 1 Dopamine agonists: Pramipexole (Mirapex)a every day
Combination therapy 5 Cited medicationsb:

  • Generic amantadine

  • Carbidopa/levodopa (Sinemet)

  • Carbidopa/levodopa/entacapone

  • (Stalevo 100)

  • Entacapone (Comtan)

  • Pramipexole (Mirapex)

  • Rasagiline mesylate (Azilect)

  • Ropinirole (Requip)
No medication 1 Stated did not understand the question
a

No dose was provided.

b

Doses and frequencies varied by respondent; in other instances, no dose or frequency was selected. Therefore, dose and frequency are not listed.

LIDs indicates levodopa-induced dyskinesias; NA, not applicable.